ARCH Venture Fund X, L.P. bought $20.0M of Aspen Neuroscience (ASPE)

Executed Nov 2, disclosed Nov 3, the same day.

Value, as filed

$20.0M

1,333,333 sh across 3 lots

Executed

Nov 2

the trade date, as filed

Disclosed

Nov 3

0 days after the trade

Return, 21 sessionsiFrom the disclosed entry session; derived

–

not yet measured

Not yet measured: the 21-session window has not closed, or the prices around it are not on record.

The filer

AP ARCH Venture Fund X, L.P. 10% owner profile →

ARCH Venture Fund X, L.P. (10% owner) filed 1 Form 4 report as a reporting entity in the trailing twelve months (1 purchase, 0 sales), most often in Aspen Neuroscience, Inc. (ASPE). The largest single filing was $20.0M of ASPE (1,333,333 sh across 3 lots, as filed), executed Nov 2. The median gap between execution and disclosure was 0 days.

The name

ASPE

Aspen Neuroscience, Inc. ASPE · Healthcare · 4 filings in 24 months ticker →

Healthcare · Aspen Neuroscience, Inc. develops autologous induced pluripotent stem cell (iPSC)-derived cell replacement therapies for neurodegenerative…

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→